TrialJournal of neuro-oncology2016

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.

Regina I Jakacki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.